

## Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department

**BARCELONA, SPAIN and CAMBRIDGE, MA, May 16, 2017** – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Roger Bullock, MD, has been appointed Chief Medical Officer (CMO). This appointment strengthens the company's epigenetic leadership with a veteran of neurological and psychiatric disorders who brings extensive clinical and medical experience in the field of Alzheimer's disease, Huntington's disease and other neurodegenerative disorders.

Dr. Bullock, a world KOL in the field, graduated in Physiological Sciences at Keble College in Oxford University and got his MB.BS at London University. He specialized in Old Age medicine and in neurodegenerative and neuropsychiatric disorders. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer's disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck. With the addition of Dr. Bullock, Dr. César Molinero will transition from his current dual position as Chief Medical and Clinical Operations Officer to concentrate on the role of Chief Clinical Officer. The medical department of Oryzon will further enhance its capabilities with the incorporation of additional clinical research associates.

In his new capacity, Dr. Bullock will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company, notably ORY-2001, an oral dual LSD1-MAOB inhibitor currently finishing Phase I in healthy volunteers. The company presented positive top line data from this clinical trial in the ADPD meeting in Vienna in March and is planning to start later this year several Phase II clinical trials with ORY-2001 in different neurodegenerative disorders, including Alzheimer's disease and Multiple Sclerosis.

Dr. Carlos Buesa, President and CEO of Oryzon said "Dr. Bullock's significant experience in neurodegenerative disorders will be transformative to Oryzon. His expertise spans a range of indications and drug types, which is immediately applicable to his new role and the clinical programs at the company. This addition underscores the commitment of the company to the development of our pipeline. We will start in a few months an ambitious clinical program, the first in its genre, to demonstrate that our epigenetic inhibitor ORY-2001 may be a meaningful therapeutic option in Alzheimer's disease, multiple sclerosis and other CNS conditions that are afflicting millions of people worldwide".

Dr Bullock said "I admire Oryzon's profound commitment and enthusiasm to improve the lives of people with neurodegenerative diseases and their innovative epigenetic platform to achieve this goal. I am very excited to join Oryzon at a time when it is rapidly expanding its medical department and look forward to

working closely with the internal team and external collaborators as we seek to further develop Proof of Concept with this novel approach that potentially addresses these significant unmet medical needs.”

#### **About Oryzon**

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit [www.oryzon.com](http://www.oryzon.com).

#### **FORWARD-LOOKING STATEMENTS**

This communication contains forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company’s securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

#### **US Contact:**

**The Trout Group**  
**Maria Kelman**  
+1 646 378 2932  
[mkelman@troutgroup.com](mailto:mkelman@troutgroup.com)

#### **Spain:**

**ATREVIA**  
**Patricia Cobo/Luis Rejano**  
+34 91 564 07 25  
[pcobo@atrevia.com](mailto:pcobo@atrevia.com)  
[lrejano@atrevia.com](mailto:lrejano@atrevia.com)

#### **The Company:**

**Anna K Baran**  
**IR Director**  
+44 (0) 752 1083 006  
[abaran@oryzon.com](mailto:abaran@oryzon.com)